SP-D

出典: meddic

サーファクタントプロテインD surfactant protein D

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/09/14 23:06:48」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Recombinant porcine surfactant protein D inhibits influenza A virus replication ex vivo.
  • Hillaire ML1, van Eijk M2, Vogelzang-van Trierum SE1, Fouchier RA1, Osterhaus AD3, Haagsman HP2, Rimmelzwaan GF4.Author information 1Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands.2Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.3Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands; Viroclinics Biosciences BV, Rotterdam, The Netherlands.4Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands; Viroclinics Biosciences BV, Rotterdam, The Netherlands. Electronic address: g.rimmelzwaan@erasmusmc.nl.AbstractInfluenza is a major burden to public health. Due to high mutation rates and selection pressure, mutant viruses emerge which are resistant to currently used antiviral drugs. Therefore, there is a need for the development of novel classes of antiviral drugs that suffer less from the emergence of resistant viruses. Antiviral drugs based on collectin-like surfactant protein D (SP-D) may fulfil these requirements. Especially porcine SP-D displays strong antiviral activity to influenza A viruses. In the present study the antiviral activity of recombinant porcine SP-D was investigated in ex vivo cultures of respiratory tract tissue infected with human influenza A virus of the H3N2 subtype. Porcine SP-D has antiviral activity in these test systems. It is suggested that porcine SP-D may be used as a venue to develop a novel class of antiviral drugs.
  • Virus research.Virus Res.2014 Mar 6;181C:22-26. doi: 10.1016/j.virusres.2013.12.032. Epub 2014 Jan 1.
  • Influenza is a major burden to public health. Due to high mutation rates and selection pressure, mutant viruses emerge which are resistant to currently used antiviral drugs. Therefore, there is a need for the development of novel classes of antiviral drugs that suffer less from the emergence of resi
  • PMID 24389095
  • Smoking and polymorphisms of genes encoding mannose-binding lectin and surfactant protein-D in patients with rheumatoid arthritis.
  • Kristiansen M, Frisch M, Madsen HO, Garred P, Jacobsen S.Author information Department of Rheumatology, 4242, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark.AbstractTo investigate whether polymorphisms in genes coding for mannose-binding lectin (MBL) and surfactant protein-D (SP-D) are associated directly or by interaction with smoking with rheumatoid arthritis (RA), anti-citrullinated peptide antibody (ACPA) positive RA, and erosive RA. MBL2 genotypes, SFTPD genotype at codon 11, and HLA-shared epitope were determined in 456 patients with rheumatoid arthritis and 533 sex- and age-matched controls. Patients were grouped according to the presence of ACPA antibodies and RA-associated bone erosions and sub-stratified according to smoking status as never or ever smokers. Odds ratios with 95 % confidence interval (OR, 95 % CI) were calculated using multiple logistic regression analyses controlling for shared epitope. The low-producing SFTPD genotype was not associated with risk of RA or ACPA positive RA, but with erosive disease in the RA patients (OR = 1.8; 95 % CI 1.1-3.0) particularly in RA ever smokers (OR = 2.4; 95 % CI 1.3-4.3). The high-producing MBL2 genotype YA/YA was associated with ACPA positive RA (OR = 1.4; 95 % CI 1.0-1.9) and erosive joint disease in RA ever smokers (OR = 1.8; 95 % CI 1.1-3.0). Genetic disposition for low SP-D was not associated with RA but with erosive RA by interaction with smoking. The genetic disposition for high MBL production was associated with ACPA positive RA irrespective of shared epitope. The findings need to be replicated but do as such offer further explanations for the clinical heterogeneity of RA.
  • Rheumatology international.Rheumatol Int.2014 Mar;34(3):373-80. doi: 10.1007/s00296-013-2904-z. Epub 2013 Nov 22.
  • To investigate whether polymorphisms in genes coding for mannose-binding lectin (MBL) and surfactant protein-D (SP-D) are associated directly or by interaction with smoking with rheumatoid arthritis (RA), anti-citrullinated peptide antibody (ACPA) positive RA, and erosive RA. MBL2 genotypes, SFTPD g
  • PMID 24264011
  • Genetic Polymorphisms of Surfactant Protein D rs2243639, Interleukin (IL)-1β rs16944 and IL-1RN rs2234663 in Chronic Obstructive Pulmonary Disease, Healthy Smokers, and Non-Smokers.
  • Issac MS, Ashur W, Mousa H.Author information Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, El Saray St., El Manial, 11956, Cairo, Egypt, mariannesamir@kasralainy.edu.eg.AbstractBACKGROUND AND OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is a complex chronic inflammatory disease that involves the activity of various inflammatory cells and mediators. It has been suggested that susceptibility to COPD is, at least in part, genetically determined. The primary aim of this study was to investigate the association between surfactant protein D (SFTPD) rs2243639, interleukin (IL)-1β rs16944 and IL-1 receptor antagonist (IL-1RN) rs2234663 gene polymorphisms and COPD susceptibility, as well as examining the association between the various IL-1RN/IL-1β haplotypes and pulmonary function tests (PFT). Secondly, we aimed to examine the influence of SFTPD rs2243639 polymorphism on serum surfactant protein D (SP-D) level.
  • Molecular diagnosis & therapy.Mol Diagn Ther.2014 Feb 7. [Epub ahead of print]
  • BACKGROUND AND OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is a complex chronic inflammatory disease that involves the activity of various inflammatory cells and mediators. It has been suggested that susceptibility to COPD is, at least in part, genetically determined. The primary aim of
  • PMID 24504887

和文文献

  • APP-078 尿路におけるサーファクタント蛋白質(SP-A、SP-D)の感染防御 : 尿路病原性大腸菌の尿路上皮への接着阻害(総会賞応募ポスター,第99回日本泌尿器科学会総会)
  • 栗村 雄一郎,西谷 千明,橋本 次朗,高橋 聡,有木 茂,高橋 素子,黒木 由夫,塚本 泰司
  • 日本泌尿器科學會雜誌 102(2), 331, 2011-03-20
  • NAID 110008612022
  • Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
  • Yamaguchi Hiroyuki,Soda Hiroshi,Nakamura Yoichi,Takasu Mineyo,Tomonaga Nanae,Nakano Hirofumi,Doi Seiji,Nakatomi Katsumi,Nagashima Seiji,Takatani Hiroshi,Fukuda Minoru,Hayashi Tomayoshi,Tsukamoto Kazuhiro,Kohno Shigeru
  • Cancer chemotherapy and pharmacology 67(2), 331-338, 2011-02
  • … In this study, we evaluated prospectively whether surfactant protein-A (SP-A) and -D (SP-D) may be new conventional predictors of the efficacy of gefitinib treatment. … METHODS: We measured serum SP-A and SP-D levels on days 0 and 29 in 40 patients with advanced NSCLC treated with 250 mg gefitinib daily. …
  • NAID 120002139476

関連リンク

SP -D は現在のところヒトにおいて肺以外の臓器、細胞での発現は報告されておらず,きわめて肺に特異的な物質であるといわれている.近年このSP -D が血液中にも存在していることが判明し,肺以外では産性,分泌されないことから血清中SP ...
地元・北陸より極上のポップスを発信する、アコースティックデュオ。 SP-D(スピィーディ) ... SAYONARA takeshi ver SAYONARA takeshi ver / SP-D takeshi DOWNLOAD版 販売 価格 200円 250円【ハイレゾ音源】

関連画像

Cessna 172 Skyhawk SP, D-ESUE, abgestellt  :Cessna 172S Skyhawk SP (D-EDDH) 01.jpgDunlop SP Winter Sport 3D | the Dunlop SP Présentation 103 SP d'enfer - mobylette File:Cessna 525 Citation 1-SP D-ITAN RECARO スポーツシート SP-D


★リンクテーブル★
国試過去問108D058
リンク元肺胞蛋白症」「サーファクタントプロテインD」「サーファクタント関連タンパク質」「SP-A
関連記事D」「SP」「S」「d

108D058」

  [★]

  • 72歳の女性。咳と労作時息切れとを主訴に来院した。 1年前から乾性咳嗽と労作時呼吸困難とを自覚し、時に朝方のこわばりも自覚していた。 1か月前から増悪するため受診した。既往歴に特記すべきことはない。意識は清明。身長 162 cm、体重62 kg。体温 36.8℃。脈拍 76/分、整。血圧 130/60 mmHg。皮疹を認めない。心音に異常を認めない。両側の背下部に fine cracklesを聴取する。両側手指の変形、腫脹および圧痛は認めない。血液所見:赤血球 269万、 Hb 8.7 g/dl、Ht 25%、白血球9,700(桿状核好中球 5%、分葉核好中球 74%、好酸球 2%、単球 4%、リンパ球 13% )、血小板 22万。血液生化学所見:総蛋白 6.8 g/dl、アルブミン 2.8 g/dl、AST 22 IU/l、 ALT 12 IU/l、LD 253 IU/l(基準 176~ 353)、尿素窒素 18 mg/dl、クレアチニン 1.1mg/dl、尿酸 5.9 mg/dl、脳性ナトリウム利尿ペプチド〈BNP〉10 pg/ml(基準 18.4以下 )、 KL-6 996 U/ml(基準 500未満 )。免疫血清学所見: CRP 8.7 mg/dl、リウマトイド因子RF〉315 IU/ml(基準 20未満 )、抗 CCP抗体 65 U/ml(基準 4.5未満 )、抗核抗体 80倍 (基準 20以下 )、サーファクタントプロテインDSP-D〉178 ng/ml(基準 0~109)。動脈血ガス分析 ( room air): pH 7.47、PaCO2 34 Torr、PaO2 63 Torr、HCO3-24 mEq/l。呼吸機能検査所見:% VC 63%、 FEV1% 79%、% DLco 35.6%。胸部エックス線写真 (別冊 No.29A)と肺野条件の胸部単純 CT(別冊 No.29B)とを別に示す。
  • 治療薬として適切なのはどれか。2つ選べ。



[正答]


※国試ナビ4※ 108D057]←[国試_108]→[108D059

肺胞蛋白症」

  [★]

alveolar proteinosispulmonary alveolar proteinosis, PAP
肺胞タンパク症肺胞タンパク質症
[show details]

病因

  • 肺胞貯留物には肺胞マクロファージが認められ、これの機能異常によるものと考えられている。

病態

症状

  • 進行性の労作時呼吸困難、咳嗽(喀痰を伴わない)、疲労、体重減少、軽度発熱。初発症状は呼吸困難(55-80%の症例で見られる)。(参考1)

身体所見

参考1
  • チアノーゼ、ばち指(いずれも25%の例で見られる)。
  • crackles(50%の例で見られる)

検査

  • 胸部単純X線:両肺野対称性、中下肺野中心に浸潤影。両肺門から広がるbutterfly shadow
  • 胸部単純CT:不均等なすりガラス陰影。メロンの皮様網目状陰影crazy paving appearance
[show details]
  • 肺胞洗浄液 BAL:白濁液。
[show details]

治療

  • DLCO低下、PaO2低下や臨床症状の悪化が見られる場合、肺胞洗浄療法
  • ステロイドは無効であり禁

参考

  • 1. [charged] 成人における肺胞蛋白症の臨床症状および病因 - uptodate [1]
  • 2. [charged] 成人における肺胞蛋白症の診断および治療 - uptodate [2]
  • 3. [charged] 小児における肺胞蛋白症 - uptodate [3]


国試



サーファクタントプロテインD」

  [★]

surfactant protein D SP-D
KL-6, SP-A。サーファクタントプロテイン
  • II型肺胞上皮細胞が分泌するサーファクトプロテインの一種。
  • 肺の線維化のマーカーとして用いられる。

意義

高値

  • 特発性間質性肺炎(87%)、膠原病関連間質性肺臓炎(71%)、肺胞蛋白症(80%)、過敏性肺臓炎、放射線肺臓炎 (検査の本)


サーファクタント関連タンパク質」

  [★]

surfactant protein
[[]]


SP-A」

  [★]

surfactant protein A
サーファクタントプロテインA
KL-6, SP-D



D」

  [★]


WordNet   license wordnet

「the 4th letter of the Roman alphabet」
d

PrepTutorEJDIC   license prepejdic

「deuteriumの化学記号」


SP」

  [★]

PrepTutorEJDIC   license prepejdic

「Shore Patrol / Specialist」

S」

  [★]

WordNet   license wordnet

「the 19th letter of the Roman alphabet」
s

PrepTutorEJDIC   license prepejdic

「sulfurの化学記号 / {略}South[ern]」


d」

  [★]

PrepTutorEJDIC   license prepejdic

「(おもに人称代名詞・固有名詞(人名),thereの後で)had, wouldの短縮形 / (疑問文でwhere,what,whenの後で)didの短縮形;Where'd he go?=Where did he go?」


"http://meddic.jp/SP-D" より作成


★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡